Prenetics Global Limited

Equities

PRE

KYG722451229

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 29/06/2024 am IST 5-day change 1st Jan Change
5.92 USD -2.95% Intraday chart for Prenetics Global Limited -1.33% +0.17%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Earnings Flash (PRE) PRENETICS LIMITED Posts Q1 Revenue $6.4M MT
Prenetics Global Limited Announces Board Appointments CI
Prenetics Global Limited Reaffirms Revenue Guidance for the Year 2024 CI
Prenetics Global Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Prenetics Global Limited Announces Committee Resignations CI
Prenetics Global Limited Reports Impairment Loss of Goodwill for the Fourth Quarter Ended December 31, 2023 CI
Prenetics Global Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Prenetics Global Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (PRE) PRENETICS LIMITED Reports Q4 Revenue $5.4M MT
Prenetics Global Enters Preliminary Agreement With Metavisionaries on Space Research MT
Prenetics Global Limited Announces Board Appointments CI
Earnings Flash (PRE) PRENETICS LIMITED Reports Q3 Revenue $4.9M MT
Prenetics Global Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cantor Fitzgerald Adjusts Prenetics Global Price Target to $4 From $6, Maintains Overweight Rating MT
Earnings Flash (PRE) PRENETICS LIMITED Reports Q2 Revenue $5.7M MT
Prenetics Global Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Traders Assess Russia Turmoil, Driving Quiet Premarket Action for US Equity Futures MT
Top Premarket Gainers MT
Prenetics Global Forms JV With Hong Kong University Professor for Multi-Cancer Early Detection Screening MT
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establishes USD 200 Million Joint Venture Insighta for Breakthrough Multi-Cancer Early Detection Screening CI
Prenetics Global Limited Appoints Joel Neoh as Chief Consumer Officer CI
Earnings Flash (PRE) PRENETICS LIMITED Reports Q1 Revenue $17.7M MT
Prenetics Global Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Prenetics Global Limited's Equity Buyback Plan announced on November 30, 2022. CI
Tranche Update on Prenetics Global Limited's Equity Buyback Plan announced on November 30, 2022. CI
Chart Prenetics Global Limited
More charts
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.92 USD
Average target price
9 USD
Spread / Average Target
+52.03%
Consensus
  1. Stock Market
  2. Equities
  3. PRE Stock
  4. News Prenetics Global Limited
  5. Prenetics Global Enters Preliminary Agreement With Metavisionaries on Space Research